Bacteriophage treatment and reduction in inflammatory response
AssigneesWestern Sydney Local Health District, The Wetmead Institute for Medical Research
InventorsChing Yu Lin, Jonathan Ripley Iredell
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation.
Claims16
A method for determining efficacy of a bacteriophage formulation to reduce inflammatory response in a subject receiving bacteriophage therapy to treat an inflammatory bacterial infection, the method comprising:
- a) obtaining a first gene expression profile for two or more informative genes in a first biological sample, wherein the first biological sample is obtained from the subject prior to administration of the bacteriophage therapy;
- b) obtaining a subsequent gene expression profile for the two or more informative genes in one or more subsequent biological samples, wherein the one or more subsequent biological samples are obtained from the subject after administration of the bacteriophage therapy;
- c) correlating the first gene expression profile and the subsequent gene expression profile, wherein said correlating step comprises assigning the difference in the first and subsequent gene expression profiles a positive, intermediate, or negative assay score;
- and
- d) treating the patient based on the positive, intermediate, or negative assay score wherein treatment comprises therapeutic intervention;
- wherein:
- a positive assay score is indicative that the bacteriophage formulation is efficacious in reducing inflammatory response in the subject and treating a subject with a positive assay score at step d) comprises administering the bacteriophage formulation to the subject;
- and
- a negative or intermediate assay score is indicative that the bacteriophage formulation is not efficacious in reducing inflammatory response in the subject and treating a subject with a negative or intermediate assay score at step d) comprises a therapeutic intervention which is different to the bacteriophage formulation;
- and
- wherein the therapeutic intervention at step d) comprises administering one or more of an antibiotic, bacteriophage therapy, and an immunomodulatory treatment to the subject.
Dependencies are inferred from the claim text.